Latest news with #ChrisGrisanti
CNBC
5 days ago
- Business
- CNBC
Bullish IPO is the final ingredient to make a market bubble, says MAI's Chris Grisanti
Chris Grisanti, MAI Capital Management chief market strategist, joins 'Power Lunch' to discuss the two conflicting market narratives, how much stock buybacks are propelling this equity market and much more.
CNBC
06-08-2025
- Business
- CNBC
Markets will move higher in near to intermediate term, says MAI Capital's Chris Grisanti
Chris Grisanti, MAI Capital Management chief market strategist, joins 'Power Lunch' to discuss how value investors are supposed to thrive in today's growth environment, where investors can find value and much more.
CNBC
01-07-2025
- Business
- CNBC
Good time to be cautious on stocks rather than reach for more performance, says MAI's Chris Grisanti
Chris Grisanti, MAI Capital Management chief market strategist, joins 'Power Lunch' to discuss why the recent rally in equities might not last.
CNBC
30-05-2025
- Business
- CNBC
China-U.S. tariff talks need quiet period before leader negotiations: Longview's Dewardric McNeal
MCC Global Enterprises' Michelle Caruso-Cabrera, MAI Capital's Chris Grisanti and Longview Global's Dewardric McNeal, join 'Power Lunch' to discuss Elon Musk's sendoff from DOGE, challenges with China negotiations and much more.
CNBC
01-05-2025
- Business
- CNBC
These two health-care names work in a 'difficult' market, says MAI Capital Management strategist
In this volatile environment, there could be big opportunities in two health-care names, according to Chris Grisanti, MAI Capital Management's chief market strategist. Stocks have been rocky amid fears about President Donald Trump' s high-tariff policy and the economy. On Thursday, equities moved up again after investors reacted to strong earnings from two tech titans, Meta Platforms and Microsoft , out after the bell Wednesday. Grisanti said his health-care plays will work best "when the market gets more difficult again." He gave his two buys, and one name he's avoiding, during the " Three Stock Lunch " segment on CNBC's " Power Lunch " Tuesday. AbbVie The global biopharmaceutical company has done a great job of replacing its blockbuster anti-inflammatory drug Humira, which has faced declining sales since it lost patent protection in 2023, Grisanti said. AbbVie now has two new drugs, Skyrizi and Rinvoq. The company posted first-quarter earnings and revenue last week that topped Street expectations. It also raised its full-year earnings-per-share guidance. AbbVie also announced in February it will invest at least $10 billion in manufacturing in the United States, including four new plants. "They've got a great management [team] there," Grisanti said. "They're mixing up the product line and so that should be real strong." ABBV YTD mountain AbbVie While shares have moved higher in recent days, they still have "a ways to go," he said. The stock lost nearly 7% in April. It is up more than 9% year to date and has a dividend yield of 3.36% UnitedHealth UnitedHealth Group is currently "in the penalty box, for good reason," Grisanti said. Shares have been pummeled since mid-April, when the health-care provider cut its annual profit forecast due to higher-than-expected medical costs. The stock hit a 52-week low on Thursday and is down more than 20% year to date. It has a 2.04% dividend yield. "This is a very rare chance to get this stock, which has great management, terrific 20-year growth profile, at a cheap valuation," Grisanti said. Booking Holdings The last name on Grisanti's list is one that he would not recommend right now: Booking Holdings . The online travel booking provider beat on both the top and bottom lines when it reported first-quarter results on Tuesday. Its gross bookings narrowly topped expectations. However, tariffs are going to start hitting corporate earnings this summer, Grisanti said. "Travel is about the most discretionary category we have," he said. "It's a great company, but I don't want to be owning it if we're sliding towards a recession." Shares are up 3% so far this year.
